Recursion posts Q2 2026 results, Genentech advances first neuroscience target

Recursion Pharmaceuticals reported second quarter 2026 results on August 5, 2026, covering the period ended June 30, 2026, alongside a business update disclosed in an 8-K filing.

The company said Genentech has exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target into a small molecule early discovery program.¹ This built on work in which Recursion, in partnership with Roche and Genentech, built the first whole-genome CRISPR knockout map generated from a subset of over 1 trillion internally manufactured iPSC-derived neuronal cells.¹ To date, Recursion has achieved $216 million in upfront and milestones payments from the Roche and Genentech collaboration, which includes up to 40 potential small molecule discovery programs, each carrying the potential for more than $300 million in development, commercialization, and net sales milestones as well as tiered royalties up to high single digits per small molecule program for Recursion.¹

On the pipeline, REC-4881 has received both Orphan Drug Designation and Fast Track Designation from the US FDA¹ for familial adenomatous polyposis, and discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26.¹ Separately, with the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors will be initiated in the second half of 2026.¹

Financially, cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026 compared to $753.9 million as of December 31, 2025¹, and net loss was $131.0 million for the second quarter of 2026, compared to a net loss of $171.9 million for the second quarter of 2025.¹ The company is lowering its cash operating expense guidance for the full year 2026 by $15 million to $375 million based on additional identified operating efficiencies.¹